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Introduction
Infertility, a disease characterized by the 
inability to have a child, affects one in six 
couples and will likely rise as the postpone-
ment of childbearing increases in developed 
regions of the world (Chandra et al. 2005; 
Evers 2002; Pinnelli and Di Cesare 2005). 
Even among fertile women, 22% of preg-
nancies fail before they can be clinically 
recognized (Wilcox et al. 1988). The asso-
ciated health care cost of infertility is in the 
billions of dollars per year and does not 
include the tremendous physical and psycho-
logical burden placed on the couple. This 
highlights the public health importance of 
understanding risk factors that may impair the 
ability to have a child.
It is well appreciated that environmental 
exposures are potential risk factors for infertility 
and adverse pregnancy outcomes. Human and 
experimental animal studies identify several 
classes of chemicals that adversely impact 
fertility and pregnancy. Recently, the American 
College of Obstetricians and Gynecologists 
(ACOG) and the American Society for 
Reproductive Medicine (ASRM) issued a Joint 
Committee Opinion on “Exposure to Toxic 
Environmental Agents” which emphasized 
that exposure to environmental chemicals 
was  ubiquitous, and that preconception and 
prenatal exposure can have a profound effect 
on reproductive health (ACOG Committee 
2013). The Joint Committee Opinion 
concluded that ACOG and ASRM, along 
with scientists and other clinical practitioners, 
noted the need for timely action to identify and 
reduce exposure to environmental agents while 
addressing the consequences of exposure.
One class of environmental chemicals 
for which there is concern related to its risk 
of adverse reproductive and developmental 
effects are the ortho-phthalates (herein 
referred to as phthalates), a family of multi-
functional chemicals widely used in personal 
care and consumer products. Human 
exposure to phthalates is widespread and 
occurs through multiple routes, including 
ingestion, inhalation, dermal contact, and 
parenteral exposure from medical devices 
containing phthalates (CDC 2013; Hauser 
and Calafat 2005). The low-molecular-
weight phthalates, such as diethyl phthalate 
(DEP), di-n-butyl phthalate (DnBP), and 
di-iso-butyl phthalate (DiBP) are principally 
used in personal care products (e.g., body 
lotions, cosmetics, shampoos, deodorants) 
and as solvents and plasticizers for cellulose 
acetate, varnishes and coatings, including 
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Background: Evidence from both animal and human studies suggests that exposure to phthalates 
may be associated with adverse female reproductive outcomes.
oBjective: We evaluated the associations between urinary concentrations of phthalate metabolites 
and outcomes of assisted reproductive technologies (ART).
Methods: This analysis included 256 women enrolled in the Environment and Reproductive 
Health (EARTH) prospective cohort study (2004–2012) who provided one to two urine samples 
per cycle before oocyte retrieval. We measured 11 urinary phthalate metabolites [mono(2-
ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-
ethyl-5-oxohexyl) phthalate (MEOHP), mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), 
mono-isobutyl phthalate (MiBP), mono-n-butyl phthalate (MBP), monobenzyl phthalate (MBzP), 
monoethyl phthalate (MEP), monocarboxyisooctyl phthalate (MCOP), monocarboxyisononyl 
phthalate (MCNP), and mono(3-carboxypropyl) phthalate (MCPP)]. We used generalized linear 
mixed models to evaluate the association of urinary phthalate metabolites with in vitro fertilization 
(IVF) outcomes, accounting for multiple IVF cycles per woman.
results: In multivariate models, women in the highest as compared with lowest quartile of 
MEHP, MEHHP, MEOHP, MECPP, ∑DEHP (MEHP + MEHHP + MEOHP + MECPP), and 
MCNP had lower oocyte yield. Similarly, the number of mature (MII) oocytes retrieved was lower 
in the highest versus lowest quartile for these same phthalate metabolites. The adjusted differences 
(95% CI) in proportion of cycles resulting in clinical pregnancy and live birth between women in 
the fourth versus first quartile of ∑DEHP were –0.19 (–0.29, –0.08) and –0.19 (–0.28, –0.08), 
respectively, and there was also a lower proportion of cycles resulting in clinical pregnancy and live 
birth for individual DEHP metabolites.
conclusions: Urinary concentrations of DEHP metabolites were inversely associated with oocyte 
yield, clinical pregnancy, and live birth following ART.
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coatings used for time release in some 
orally administered medications (Hauser 
and Calafat 2005). High-molecular-weight 
phthalates [e.g., di(2-ethylhexyl) phthalate 
(DEHP) and di-isononyl phthalate (DiNP)] 
are used primarily as plasticizers in the manu-
facture of flexible vinyl, which, in turn, is 
used in consumer products, flooring and wall 
coverings, food contact applications, and 
medical devices (Hauser and Calafat 2005). 
Because these phthalate plasticizers are not 
chemically bound to the polymer chain, 
they leach, migrate, or off gas, thus leading 
to human exposure (Koch et al. 2006). 
Phthalates have a short half-life (i.e., hours) 
and are rapidly metabolized and excreted in 
urine and feces (Hauser and Calafat 2005; 
Silva et al. 2006).
Some phthalates are anti-androgenic and 
adversely affect the development of the male 
fetus and male fertility following gestational 
exposure in the rat to high doses of phthalates 
(Fisher 2004). However, the impact of phthal-
ates on female reproductive health, fertility, 
and early pregnancy outcomes is much less 
studied (Ema et al. 2000; Gray et al. 2006; 
Lovekamp and Davis 2001; Svechnikova et al. 
2007). In the study by Gray et al. (2006), 
oral administration of DnBP to female Long 
Evans hooded rats, from weaning through 
puberty, mating, and gestation, induced mid-
pregnancy abortions with up to a 90% reduc-
tion in the percentage of females delivering 
live pups at 1,000 mg/kg/day. The decreased 
litter size was associated with reduced serum 
progesterone levels and ovarian progesterone 
production on gestational day 13. Other 
studies have shown a reduction in serum levels 
of progesterone and estradiol in prepubertal 
female rats dosed with DEHP for 10 days 
(Svechnikova et al. 2007), and increased post-
implantation embryo loss was reported in rats 
treated with DnBP (Ema et al. 2000).
A limited number of epidemiologic 
studies have reported associations between 
measures of exposure to some phthalates 
with decreased rates of pregnancy and risk of 
miscarriage, as well as complications such as 
anemia, toxemia, and preeclampsia in women 
(Heudorf et al. 2007). A recent human 
study reported an association between higher 
urinary concentrations of mono(2-ethylhexyl) 
phthalate (MEHP), a metabolite of DEHP, 
and early pregnancy loss (Toft et al. 2012). 
However, as far as we are aware, no human 
studies have explored the association of 
phthalate exposure with very early pregnancy 
outcomes, such as oocyte fertilization and 
embryo implantation. 
In the present analysis, we assessed 
data from our ongoing prospective cohort 
study, the Environment and Reproductive 
Health (EARTH) study, using assisted 
reproductive technologies (ART) as a model 
of human reproduction to explore the rela-
tionship between environmental exposures 




Study participants were recruited into the 
EARTH Study between November 2004 and 
April 2012 from patients undergoing in vitro 
fertilization (IVF) at the Massachusetts 
General Hospital (MGH) Fertility Center. 
All women > 18 years of age and < 46 years 
(at enrollment) were eligible to participate 
(approximately 60% of those contacted by 
the research nurses participated in the study). 
Women must have contributed their own 
oocytes and at least one urine sample for the 
measurement of phthalate metabolites during 
an IVF cycle to be included in the present 
analysis. From 429 eligible IVF cycles, we 
excluded IVF cycles for which women used 
an egg donor (n = 18) or cryo-thaw cycles 
(n = 35), and those missing information on 
body mass index (BMI) (n = 1). This left us 
with 375 IVF cycles with complete informa-
tion on exposure, outcome, and all covari-
ates. The EARTH study was approved by the 
Human Studies Institutional Review Boards 
of the MGH, Harvard School of Public 
Health (HSPH), and the Centers for Disease 
Control and Prevention (CDC). Participants 
signed an informed consent after the study 
procedures were explained by a research nurse 
and all questions were answered.
Clinical Data
Clinical information at entry into the study 
and after each IVF cycle was abstracted from 
the patient’s electronic medical record by the 
research nurse. At study entry and each IVF 
cycle, a blood sample was drawn on the third 
day of the menstrual cycle, and the serum 
was analyzed for follicle-stimulating hormone 
(FSH) with an automated electrochemilu-
minescence immunoassay at the MGH Core 
Laboratory as previously described (Mok-Lin 
et al. 2010). At entry into the EARTH Study 
and subsequent to an infertility evaluation, 
each patient was given an infertility diag-
nosis by a physician at the MGH Fertility 
Center according to the Society for Assisted 
Reproductive Technology (SART) definitions 
as previously described (Mok-Lin et al. 2010; 
SART 2013). At entry, the participant’s date 
of birth was collected and weight and height 
were measured by the nurse. BMI was calcu-
lated as weight (in kilograms) per height (in 
meters) squared.
At each IVF cycle, depending on clinical 
indications and factors such as age and infer-
tility diagnosis, women underwent one of 
three IVF treatment protocols: a) luteal-phase 
gonadotropin-releasing hormone (GnRH) 
agonist (low-, regular-, or high-dose leup-
rolide acetate; Lupron), b) follicular-phase 
GnRH-agonist/Flare stimulation, and 
c) GnRH-antagonist. For each cycle, on the 
day of ovulation trigger with human chori-
onic gonadotropin (hCG), serum peak 
estradiol was measured with an automated 
electrochemiluminescence immunoassay at 
the MGH Core Laboratory (Mok-Lin et al. 
2010). Couples underwent assisted repro-
duction with conventional IVF or intra-
cytoplasmatic sperm injection (ICSI) (ASRM 
2015; Bhattacharya et al. 2001). The ICSI 
technique was originally developed to treat 
cases of severe male factor infertility (one or 
more severely decreased semen parameters) 
but is now used for certain other indications 
(Practice Committees of the American Society 
for Reproductive Medicine and Society for 
Assisted Reproductive Technology 2012). 
After egg retrieval, embryologists classified 
oocytes as germinal vesicle, metaphase I, meta-
phase II (MII), or degenerated. Embryologists 
determined fertilization 17–20 hr after 
insemination. Fertilization was confirmed by 
the presence of a fertilized oocyte with two 
pronuclei. Embryos were monitored for cell 
number and morphological quality [1 (best) 
to 5 (worst)] on day 2 and 3. For analysis 
we classified embryos as best quality if they 
had four cells on day 2, eight cells on day 3, 
and a morphologic quality score of 1 or 2 on 
days 2 and 3 (Veeck and Zaninovic 2003). 
An overall score of 1 or 2 was considered 
high quality, 3 was considered intermediate 
quality, and 4 or 5 indicated poor-quality 
embryos. If a cycle lacked information on 
day 2 or day 3 embryo quality (e.g., failed 
fertilization, day 2 transfer), they were classi-
fied as having no best-quality embryos. We 
defined implantation as a serum β-hCG level 
> 6 mIU/mL typically measured 17 days 
(range, 15–20 days) after egg retrieval, 
clinical pregnancy as the presence of an 
intrauterine pregnancy confirmed by ultra-
sound at approxi mately 6 weeks gestation, 
and live birth as the birth of a neonate on or 
after 24 weeks gestation. Before the start of 
the EARTH study, we determined that the 
infertility medications do not contain phthal-
ates (Kelley et al. 2012), and we tested the IVF 
equipment and medical supplies for phthalates 
(data not shown). We did not identify these as 
potential sources of exposure.
Urinary Phthalate Metabolite 
Measurements
Two urine samples were collected during 
each IVF cycle (between days 3 and 9 of the 
gonadotropin phase and on the day of the 
oocyte retrieval). The median time between 
the two urine samples collected per cycle 
was 8 days (interquartile range, 6–9), Urine 
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samples were collected between November 
2004 and April 2012. Urine was collected in 
a sterile polypropylene cup. After measuring 
specific gravity (SG) using a handheld refrac-
tometer (National Instrument Company 
Inc.), the urine was divided into aliquots 
and frozen at –80°C. Samples were shipped 
on dry ice overnight to the CDC (Atlanta, 
GA) for the quantification of concentrations 
of MEHP, mono(2-ethyl-5-hydroxyhexyl) 
phthalate (MEHHP), mono-2-ethyl-5-oxo-
hexyl phthalate (MEOHP), mono(2-ethyl-
5-carboxypentyl) phthalate (MECPP), 
mono(3-carboxypropyl) phthalate (MCPP), 
monocarboxyisooctyl phthalate (MCOP), 
monocarboxyisononyl phthalate (MCNP), 
monobenzyl phthalate (MBzP), monoethyl 
phthalate (MEP), mono-isobutyl phthalate 
(MiBP), and mono-n-butyl phthalate 
(MBP). The analytical approach, based on 
solid phase extraction coupled with high 
performance liquid chromatography-isotope 
dilution tandem mass spectrometry, followed 
standard quality assurance/quality control 
procedures as previously described (Silva 
et al. 2007). The limits of detection (LOD) 
were 0.5–1.2 μg/L (MEHP), 0.2–0.7 μg/L 
( MCOP,  MEHHP,  and  MEOHP) , 
0.2–0.6 μg/L (MECPP and MCNP), 
0.1–0.2 μg/L (MCPP), 0.2–0.3 μg/L 
(MBzP and MiBP), 0.4–0.8 μg/L (MEP), 
and 0.4–0.6 μg/L (MBP). We calculated the 
molar sum of DEHP metabolites (∑DEHP) 
by dividing each metabolite concentration 
by its molecular weight and then summing: 
{[MEHP × (1/278.34)] + [MEHHP × 
(1/294.34)] + [MEOHP × (1/292.33)] + 
[MECPP × (1/308.33)]}. MCPP is a metabo-
lite of di-n-octyl phthalate (DnOP) and a 
nonspecific metabolite of high molecular 
weight phthalates, MCOP is a metabolite 
of DiNP, and MCNP is a metabolite of 
di-isodecyl phthalate (DiDP).
Statistical Analysis
Demographic characteristics of the study 
participants and clinical characteristics 
(cycle- and embryo-level) were reported using 
mean ± SD or percentages. Cycle-specific 
urinary concentrations of phthalate metabo-
lites were calculated using the geometric mean 
(GM) of the two urinary phthalate concentra-
tions from each IVF cycle. Urinary phthalate 
metabolite concentrations below the LOD 
were replaced with a value equal to the LOD 
divided by the square root of 2 (Hornung 
and Reed 1990). Although there are newer 
methods to replace values below the LOD 
(Cole et al. 2009; Nie et al. 2010), our use 
of quartiles minimized the impact of samples 
less than LOD; essentially all women who 
were below the LOD were classified into the 
first quartile given that the lowest detection 
limit was 75.5% (for MEHP). For all other 
metabolites, the lowest quartile included 
women with concentrations below the LOD 
and others with low concentrations.
To adjust for urinary dilution, the following 
formula was used: Pc = P[(1.015 – 1)/SG – 1], 
where Pc is the SG-corrected phthalate 
metabolite concentration (micrograms per 
liter), P is the measured phthalate metabolite 
concentration (micrograms per liter), and 
1.015 is the mean (and median) SG level in 
the study population (Smith et al. 2012). 
We used SG-corrected phthalate metabolite 
 concentrations in all analyses.
We fit multivariate generalized linear 
mixed models with random intercepts to 
evaluate the association between urinary 
phthalate metabolites and IVF outcomes. 
These models allow for the use of multiple 
outcome observations per individual while 
accounting for within-person correlations 
in outcomes. These models are also appro-
priate and can provide unbiased estimates in 
the presence of an unbalanced design (e.g., 
different number of cycles contributed per 
woman) when imbalance in the number of 
IVF cycles is not completely random, and the 
lack of balance can be accurately predicted 
by all measured covariates in the adjusted 
model. A linear distribution and identity link 
function was specified for peak estradiol, a 
Poisson distribution and log link function 
were specified for oocyte counts, and a 
binomial distribution and logit link function 
were specified for fertilization, embryo 
quality, and clinical outcomes. Tests for 
trend were conducted across quartiles using 
the median urinary phthalate metabolite 
concentration in each quartile as a continuous 
variable in the regression models. All results 
are presented as population marginal means, 
adjusted for covariates.
Confounding was evaluated using prior 
knowledge and descriptive statistics from 
our cohort through the use of directed 
acyclic graphs. The following covariates 
were considered for inclusion in the final 
model: maternal age (continuous), BMI 
(continuous), smoking status (ever smoked 
and never smoked), year of treatment 
(2004–2006, 2007–2009, 2010–2012), day 3 
FSH (continuous), treatment protocol type 
(luteal phase or Flare/GnRH antagonist), and 
primary infertility diagnosis (female factor, 
male factor, and unexplained). Variables 
were included in the final model if they were 
associated with phthalate exposure in our 
population, were suspected to be associated 
with phthalate exposure based on previous 
research, or were strong predictors of the 
outcome. To test whether the associations of 
urinary phthalate metabolite concentrations 
with IVF outcomes were modified by ICSI, a 
product of quartiles of phthalate and a binary 
variable representing the presence or absence 
of ICSI was entered into the models. Given 
our limited power, a suggestion of inter-
action was considered if the p-value for this 
interaction term was < 0.10. As a sensitivity 
analysis we evaluated the association between 
urinary phthalate metabolite concentrations 
and probability of implantation, clinical 
pregnancy, and live birth per embryo transfer 
to assess whether any association between 
urinary phthalates and clinical outcomes 
remained after excluding early failures. We 
conducted all statistical analyses using SAS 
version 9.2 (SAS Institute Inc., Cary, NC) 
and considered two-sided significance levels 
< 0.05 as statistically significant.
Results
Our analysis included 256 women who were 
on average 35.3 years of age; 72% had never 
smoked and 82% were Caucasian (Table 1). 
The primary SART diagnosis was 37% male 
factor, followed by 33% unexplained infer-
tility and 30% female factor infertility. The 
women underwent a total of 375 IVF cycles, 
with 179 women (69%) contributing 1 cycle, 
47 women (18%) contributing 2 cycles, 21 
women (8%) contributing 3 cycles, 7 women 
(3%) contributing 4 cycles, 1 woman (< 1%) 
Table  1.  Demographic characteristics and 
primary SART diagnosis among 256 women in 
the Environment and Reproductive Health Study 
enrolled between 2004 and 2012.
Characteristic n (%)
Age at study entry (years) 
Mean ± SD 35.3 ± 3.93
Range 21–43
Age ≥ 37 95 (37%)
BMI (kg/m2) 
Mean ± SD 24.1 ± 4.34
Range 16.1–42.4
Underweight or normal (< 25) 180 (70%)
Overweight or obese (≥ 25) 76 (30%)
Smoking
Never smoked 185 (72%)
Ever smoked
Current smoker 6 (2%)
Former smoker 65 (26%)
Race 
Caucasian 211 (82%)
Black/African American 6 (2%)
Asian 21 (8%)
Other 18 (7%)
Primary SART diagnosis at study entry 
Female factor 77 (30%)
Diminished ovarian reserve 18 (7%)
Ovulation disorders 22 (9%)
Endometriosis 17 (7%)
Uterine disorders 2 (1%)
Tubal factor 18 (7%)
Male infertility 95 (37%)
Unexplained 84 (33%)




Abbreviations: BMI, body mass index; SART, Society for 
Assisted Reproductive Technology (SART 2013).
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contributing 5 cycles, and 1 woman (< 1%) 
contributing 6 cycles. The luteal-phase treat-
ment protocol was used for 67% of IVF 
cycles and ICSI (fertilization method) was 
used for 55% of IVF cycles (Table 2). Among 
cycles with male factor as the primary infer-
tility diagnosis, 88% used ICSI as compared 
to 40% and 31% using ICSI with female 
factor or unexplained infertility diagnoses, 
respectively. A total of 673 urine samples 
were collected from the 256 women; 79% of 
the IVF cycles had 2 urine samples and 21% 
IVF cycles had only 1 urine sample per cycle. 
The distribution of each urinary phthalate 
metabolite in our population is shown in 
Table 3. An overview of the 375 IVF cycles is 
shown in Figure 1. In brief, 337 cycles of the 
initial 375 cycles underwent embryo transfer 
(90%). Of the cycles that underwent embryo 
transfer, the percent resulting in implanta-
tion, clinical pregnancy, and live birth were 
59%, 53%, and 44%, respectively.
In multivariable models adjusted for 
age, BMI, smoking status, and infertility 
diagnosis, only MCNP was associated 
with peak estradiol (p-trend = 0.009). The 
adjusted mean peak estradiol was 2,225 μg/L 
[95% confidence interval (CI): 2,036, 2,414] 
in quartile (Q) 1 compared to 1,902 μg/L 
(95% CI:1,710, 2,094) in quartile 4 (p-value 
for Q4 vs. Q1 = 0.02) (results not shown). 
In adjusted multivariable models, there 
were statistically significant associations of 
∑DEHP, MEHP, MEHHP, MEOHP, 
MECPP, and MCNP with reduced total 
oocyte yield for the 4th compared with 
the 1st quartile (Figure 2). Consistent with 
the decrease in oocyte yield, there were 
decreased numbers of MII oocytes retrieved 
in quartile 4 compared with quartile 1 for 
∑DEHP, MEHP, MEHHP, MEOHP, 
MECPP, and MCNP (Figure 2). The total 
number of fertilized oocytes was significantly 
lower in quartile 4 compared with quartile 1 
Table 3. Distribution of urinary phthalate metabolite concentrations (metabolite or molar sum) measured among 256 women in the Environment and Reproductive 
Health Study enrolled between 2004 and 2012.
Phthalate Units nb LOD % Detectc
SG-adjusted Unadjusteda
Median (IQR) Maximum Median (IQR) Maximum
∑DEHP metabolites μmol/L 375 — — 0.19 (0.10, 0.42) 5.60 0.20 (0.09, 0.44) 7.52
MEHP μg/L 375 0.5–1.2 77.1 2.88 (1.37, 6.87) 99.3 2.72 (1.30, 6.91) 130
MEHHP μg/L 375 0.2–0.7 99.7 15.7 (7.75, 35.0) 561 16.3 (7.07, 38.2) 582
MEOHP μg/L 375 0.2–0.7 99.6 10.5 (5.48, 25.4) 306 11.3 (4.92, 25.7) 387
MECPP μg/L 375 0.2–0.6 96.7 26.3 (14.6, 57.2) 761 29.2 (12.9, 62.9) 1,190
MEP μg/L 375 0.4–0.8 100 49.3 (21.5, 129) 3,481 52.2 (20.8, 133) 2,537
MBP μg/L 375 0.4–0.6 97.0 12.9 (7.32, 20.8) 435 12.6 (6.40, 26.3) 250
MCPP μg/L 375 0.1–0.2 96.7 3.22 (1.80, 6.64) 202 3.63 (1.77, 7.76) 179
MiBP μg/L 375 0.2–0.3 96.7 6.66 (3.50, 12.0) 49.7 7.03 (3.14, 14.6) 76.3
MBzP μg/L 375 0.2–0.3 95.5 3.44 (1.75, 7.35) 121 3.99 (1.57, 7.60) 189
MCOP μg/L 337 0.2–0.7 98.6 22.8 (9.10, 57.7) 1,350 22.7 (8.00, 66.2) 2,250
MCNP μg/L 337 0.2–0.6 96.6 4.58 (2.51, 7.97) 281 4.75 (2.41, 9.18) 281
Abbreviations: IQR, interquartile range; LOD, limit of detection; n, number of IVF cycles; SG, specific gravity.
aUnadjusted concentrations presented to facilitate comparison with other studies. bGeometric mean of up to 2 urinary phthalate concentrations from each IVF cycle was used. 
cPercent of phthalate metabolite concentrations above the detection limits (n = 673 total urine samples except for MCOP and MCNP, which have 646 urine samples); total samples 
< LOD by analyte: MEHP = 154, MEHHP = 2; MEOHP = 3, MECPP = 22, MEP = 0, MBP = 20, MCPP = 22, MiBP = 22, MBzP = 30, MCOP = 9, MCNP = 22.
Table 2. Cycle-specific clinical characteristics from 375 IVF cycles among 256 women in the Environment 
and Reproductive Health Study enrolled between 2004 and 2012.
Cycle-specific characteristics (n = 375 IVF cycles)
n (%) or  
mean ± SD (range)
Treatment protocol 
Luteal phase 251 (67)
Flare 77 (20)
Antagonist 47 (13)
Number of embryos transferred
No embryos transferred 38 (10)
1 embryo 46 (12)
2 embryos 206 (55)
≥ 3 embryos 85 (23)
Embryo transfer day






Traditional IVF 161 (45)
Controlled ovarian hyperstimulation outcomes (n = 357 IVF cyclesa)
Day 3 FSH (IU/L) 7.15 ± 2.17 (0.2–15.2)
Peak estradiol (pg/mL) 2,071 ± 853 (551–5,263)
Total number of oocytes retrieved 10.91 ± 5.41 (1–32)
Mature (MII) oocytes retrieved 9.20 ± 4.65 (0–27)
Maturation rate (MII oocytes/total oocytes retrieved) 0.86 ± 0.16 (0–1)
Normal (2PN) fertilized oocytes 6.37 ± 3.66 (0–21)
Fertilization rate (2PN/MII oocytes) 0.69 ± 0.24 (0–1)
Total embryos 5.99 ± 3.75 (0–21)
Best embryos 1.48 ± 1.90 (0–13)
Pregnancy outcome (n = 375 IVF cycles)
No oocytes retrieved 18 (4.8)
Fertilization failure 9 (2.4)
Arrested embryo development or all embryos frozen 11 (2.9)
Implantation failureb 135 (36.0)
Chemical pregnancyc 21 (5.6)
Ectopic pregnancy 4 (1.1)
Spontaneous abortion 27 (7.2)
Therapeutic abortion 1 (0.3)
Stillbirth 2 (0.5)
Live birth 147 (39.2)
Abbreviations: FSH, follicle-stimulating hormone; ICSI, intra-cytoplasmic sperm injection; IVF, in vitro fertilization; 
MII, mature oocytes; PN, pronuclei. 
aFresh IVF cycles with successful egg retrieval (missing cycles include cycles failing before egg retrieval). bImplantation 
failure was defined as a negative pregnancy test (βhCG < 6 mIU/mL) 17 days following embryo transfer or insemination. 
cChemical pregnancy was defined as implantation with no subsequent clinical pregnancy.
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for MCOP and MCNP, but not the other 
phthalate metabolites (Figure 2). There was 
no interaction between use of ICSI and the 
association of phthalates with the number of 
fertilized oocytes (data not shown, p-value for 
inter action > 0.10). In multivariable models 
there were no statistically significant associa-
tions of any phthalate metabolite with percent 
of cycles with one or more high-quality 
embryos (p for trend > 0.05 for all metabo-
lites, and no point estimate comparisons were 
significant) (data not shown).
After controlling for age, BMI, smoking 
status, and primary infertility diagnosis, 
increased quartiles of ∑DEHP were associ-
ated with a reduced probability of clinical 
pregnancy and live birth such that there 
appeared to be monotonic downward 
trend (p for trend = 0.04 and 0.01, respec-
tively) (Table 4). The adjusted difference 
(95% CI) in proportion of cycles resulting 
in clinical pregnancy between women in the 
highest DEHP quartile (4th) versus lowest 
quartile (1st) was –0.19 (–0.29, –0.08), 
representing a decrease in the probability of 
clinical pregnancy from 0.57 to 0.38 (p for 
trend = 0.04). Similarly, women in this 
highest ∑DEHP quartile versus the lowest 
had a mean decrease in proportion of cycles 
resulting in live birth of 0.19 (–0.28, –0.08), 
representing a decrease from 0.47 to 0.28, 
respectively (p for trend = 0.01). There 
was a similar monotonic downward trend 
in proportion of cycles resulting in clinical 
pregnancy and live birth across increasing 
quartiles of individual DEHP metabolites, 
MEHP, MEHHP, MEOHP, and MECPP 
(Table 4). The monotonic downward trends 
between DEHP metabolites and implanta-
tion, clinical pregnancy and live birth were 
similar when analyses were restricted to cycles 
with embryo transfer (n = 337 cycles) (data 
not shown). Although concentrations of the 
other phthalate metabolites measured (MEP, 
MBP, MIBP, MBzP, MCPP, MCOP, and 
MCNP) were not significantly related to 
clinical outcomes following IVF (Table 4), 
17 of the 18 adjusted models for probability 
of implantation, clinical pregnancy, and 
live birth showed reduced proportions for 
quartile 4 compared with quartile 1. Finally, 
across all the urinary phthalate metabolites, 
there were no interactions between the use of 
ICSI and associations of phthalates with live 
birth (data not shown).
It is well appreciated that during the 
course of the study, urinary concentrations 
of some of the phthalate metabolites have 
decreased in the general population (Zota 
et al. 2014), and there may also be a temporal 
trend in IVF success. In our data set, urinary 
DEHP metabolite concentrations tended to 
be higher in earlier years, but calendar year 
was not significantly associated with IVF 
outcome. When we explored adjusting for 
calendar year in the multivariable models, 
the effect estimates remained similar and the 
conclusions remained the same (data not 
shown). To keep the most parsimonious 
model possible, we opted to exclude year in 
the final multivariable model.
Discussion
In the present study we used the model of 
IVF to investigate human reproduction and 
pregnancy outcomes, ranging chronologically 
from the number and maturity of oocytes at 
retrieval, number of fertilized embryos, and 
embryo implantation to live birth. Urinary 
metabolites of DEHP and DiDP were 
associated with decreased oocyte yield and 
number of MII oocytes at retrieval, whereas 
only metabolites of DiNP and DiDP were 
associated with reduced fertilization rate. 
There is evidence that a decreased oocyte yield 
predicts poorer IVF outcomes (Ji et al. 2013; 
Sunkara et al. 2011). Urinary concentrations 
of DEHP metabolites were associated with 
reduced probability of clinical pregnancy and 
live birth. The magnitude of this reduction 
was clinically relevant. The adjusted propor-
tion of live births in the highest quartile of 
∑DEHP was 0.28 compared with 0.47 in 
the lowest quartile. Although urinary concen-
trations of other phthalate metabolites (i.e., 
MEP, MBP, MIBP, MBzP, MCPP, and 
MCNP) were not significantly associated 
with decreased probability of implantation, 
clinical pregnancy, or live birth, nearly all 
of the models showed small to moderate 
reduced likelihood of these outcomes when 
the highest quartile was compared with the 
lowest quartile.
There are few epidemiologic studies on 
associations of phthalates with rates of preg-
nancy and miscarriage (Heudorf et al. 2007). 
A recent publication on time to pregnancy 
in a U.S. prospective cohort (LIFE study) 
did not find associations between maternal 
urinary concentrations of 14 phthalate 
metabolites and fecundity (Buck Louis et al. 
2014). They enrolled 501 couples from 2005 
through 2009 who discontinued contracep-
tion and attempted to become pregnant. They 
used time to pregnancy to assess fecundity 
and to determine the number of menstrual 
cycles required for pregnancy confirmed by 
hCG. Possible explanations for differences 
in results between our study, which found 
associations between some urinary phthalate 
Figure 1. Overview of in vitro fertilization (IVF) outcomes of 256 women (375 cycles) in the Environment and 
Reproductive Health Study enrolled between 2004 and 2012. 
Abbreviations: IUI, intrauterine insemination; IVF, in vitro fertilization; SAB, spontaneous abortion; SB, stillbirth; TAB, 
therapeutic abortion.
375 fresh IVF cycles
357 cycles with egg retrieval
9 failed fertilization cycles
348 cycles with fertilization
11 cycles no embryo transfer (2 arrested, 9 frozen)
337 cycles with embryo transfer
137 cycles no implantation
200 implantations
177 clinical pregnancies
30 cycles with pregnancy loss (1 TAB, 27 SAB, 2SB)
147 live births
23 cycles pregnancy but no clinical confirmation
18 cancelled or IVF → IUI cycles
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metabolites and reduced probability of preg-
nancy and live birth, and the LIFE study, 
which did not find associations of phthalate 
metabolites with reduced fecundity, include 
the choice of study population, differences in 
co-exposures, and the potential for unmea-
sured confounding. Our study included 
couples from a fertility clinic, whereas the 
LIFE study enrolled couples discontinuing 
contraception and attempting to become 
pregnant, excluding any couples with physi-
cian diagnosed infertility/sterility. The differ-
ences in results across studies may suggest 
that couples from an infertility clinic may 
represent a sensitive subpopulation to envi-
ronmental chemicals, specifically phthalates. 
Other explanations for differences in results 
may be related to analytical methods used 
to measure phthalate metabolites which 
varied across the two studies and potential 
co-exposures to other chemicals in the two 
study populations.
Another recent publication including 
430 couples enrolled in a Danish prospec-
tive cohort study (from 1992 through 1994) 
reported an association between urinary 
concentrations of phthalate metabolites 
and pregnancy loss (Toft et al. 2012). The 
authors explored associations of urinary 
phthalate metabolite concentrations with 
early pregnancy loss end points comparable 
with those measured in our study. In the 
Danish study, 128 women were enrolled 
after discontinuation of birth control and 
followed prospectively until a clinical preg-
nancy or for six menstrual cycles if there was 
no clinical pregnancy. Subclinical embry-
onic loss (referred to as early pregnancy loss) 
was determined through measurements of 
hCG in urine samples collected on the first 
10 days of each menstrual cycle. By phone 
interview with the women, data were also 
collected on self-reported clinical sponta-
neous abortion. Pregnancy loss was increased 
among women in the upper tertile of urinary 
MEHP concentrations [adjusted odds ratio 
(OR) = 2.87; 95% CI: 1.09, 7.57] compared 
with the lowest tertile. When early and late 
pregnancy loss were analyzed in separate 
models, the OR for urinary MEHP concen-
trations and early pregnancy loss was 40.67 
(95% CI: 4.48, 369.5) for tertile 3 compared 
with tertile 1, whereas late pregnancy loss was 
negatively associated with urinary MEHP 
(OR = 0.25; 95% CI: 0.05, 1.8 for the third 
tertile compared with the first tertile). For 
the other phthalate metabolites measured 
(MEP, MBP, MBzP, and oxidative metabo-
lites of DEHP, MEOHP, and MEHHP) 
there were also elevated, non significant, 
adjusted odds of early pregnancy loss 
[ranging from 1.13 (95% CI: 0.36, 3.59) 
for MEP to 1.64 (95% CI: 0.52, 5.20) for 
MBP and 3.11 (95% CI: 0.87, 11.09) for 
MBzP]. There were no statistically signifi-
cant associations between the other measured 
urinary phthalate metabolites and odds for 
 spontaneous abortion.
Although the results of the Danish 
study (Toft et al. 2012) and our study for 
DEHP metabolites are consistent, it should 
be cautioned that the early pregnancy loss 
end point in Danish women conceiving 
naturally was not the same as our end points 
of implantation, clinical pregnancy, and live 
birth. The authors of the Danish study urge 
caution when interpreting their results for 
MEHP because the incidence of early preg-
nancy loss in the first tertile was only 3%; 
thus they note that the very high OR for early 
pregnancy loss may be partially attributable 
to chance. Although both studies measured 
urinary phthalate metabolites in the concur-
rent conception cycle (measured on days 3 
and 9 in our study, and day 10 in the Danish 
study), there were differences in analytical 
methods for the measurement of phthalate 
metabolites that may contribute to differences 
in results across studies.
Although implantation, clinical preg-
nancy, and live birth measured in women 
are not strictly comparable with pregnancy 
loss end points measured in experimental 
animals, studies in rats—albeit at doses much 
Figure 2. Adjusted mean (95% CI) total, mature (MII), and fertilized oocyte count by quartile of urinary 
phthalate metabolites and ∑DEHP concentrations among 247 women undergoing 357 IVF cycles with 
successful egg retrieval: (A) ∑DEHP, (B) MEHP, (C) MEHHP, (D) MEOHP, (E) MECPP, (F) MCOP, (G) MCNP. 
Adjusted models control for maternal age (continuous), body mass index (continuous), smoking status 
(never, ever), and primary SART infertility diagnosis at study entry (female, male, unexplained). 
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higher than those experienced by our study 
population (Heudorf et al. 2007)—support 
associations between exposure to phthalates 
and pregnancy loss. Further support for the 
biological plausibility of the associations 
between early pregnancy loss in the epidemio-
logic studies were studies in rats that showed 
that exposure to DEHP led to reductions in 
aromatase mRNA and protein levels leading 
to a decreased conversion of testosterone to 
estradiol (Lovekamp-Swan and Davis 2003) 
and a decrease in progesterone and estra-
diol in prepubertal female rats dosed with 
DEHP (Svechnikova et al. 2007). Human 
studies have shown that low pregnancy 
Table 4. Unadjusted and adjusted mean proportion (95% CI) of cycles resulting in implantation, clinical pregnancy, and live birth by quartile of urinary DEHP 
metabolites and ∑DEHP concentrations among 256 women undergoing 375 IVF cycles.
Phthalate measure quartiles
Implantation Clinical pregnancy Live birth
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
∑DEHP metabolites (μmol/L)
Q1 (≤ 0.10) 0.63 (0.52, 0.72) 0.62 (0.50, 0.72) 0.59 (0.48, 0.69) 0.57 (0.45, 0.67) 0.50 (0.39, 0.60) 0.47 (0.36, 0.58)
Q2 (0.11–0.19) 0.54 (0.44, 0.65) 0.55 (0.44, 0.65) 0.46 (0.36, 0.57) 0.46 (0.36, 0.57) 0.44 (0.33, 0.54) 0.43 (0.32, 0.54)
Q3 (0.20–0.42) 0.51 (0.41, 0.62) 0.52 (0.41, 0.63) 0.48 (0.38, 0.59) 0.49 (0.38, 0.59) 0.39 (0.29, 0.50) 0.39 (0.29, 0.50)
Q4 (0.43–5.60) 0.48 (0.38, 0.59)* 0.49 (0.39, 0.60) 0.38 (0.28, 0.48)* 0.38 (0.28, 0.49)* 0.28 (0.20, 0.39)* 0.28 (0.19, 0.39)*
p-Trenda 0.09 0.18 0.02 0.04 0.005 0.01
MEHP (μg/L)
Q1 (≤ 1.36) 0.61 (0.50, 0.70) 0.60 (0.49, 0.70) 0.55 (0.45, 0.65) 0.54 (0.43, 0.64) 0.47 (0.37, 0.58) 0.45 (0.35, 0.56)
Q2 (1.37–2.88) 0.57 (0.46, 0.66) 0.56 (0.45, 0.66) 0.53 (0.42, 0.63) 0.52 (0.41, 0.62) 0.46 (0.35, 0.56) 0.44 (0.34, 0.55)
Q3 (2.89–6.80) 0.47 (0.37, 0.57) 0.48 (0.37, 0.58) 0.43 (0.33, 0.53) 0.43 (0.33, 0.54) 0.37 (0.27, 0.48) 0.36 (0.27, 0.47)
Q4 (6.87–99.3) 0.52 (0.42, 0.63) 0.54 (0.43, 0.65) 0.40 (0.30, 0.50)* 0.41 (0.31, 0.52) 0.30 (0.22, 0.41)* 0.30 (0.21, 0.41)
p-Trend 0.43 0.68 0.04 0.09 0.02 0.04
MEHHP (μg/L)
Q1 (≤ 7.74) 0.61 (0.50, 0.70) 0.58 (0.47, 0.69) 0.58 (0.47, 0.68) 0.55 (0.44, 0.66) 0.58 (0.47, 0.68) 0.45 (0.34, 0.56)
Q2 (7.75–15.4) 0.57 (0.46, 0.66) 0.57 (0.47, 0.67) 0.49 (0.39, 0.60) 0.50 (0.39, 0.60) 0.49 (0.39, 0.60) 0.46 (0.36, 0.57)
Q3 (15.5–34.5) 0.51 (0.41, 0.62) 0.52 (0.42, 0.63) 0.46 (0.36, 0.57) 0.47 (0.36, 0.58) 0.46 (0.36, 0.57) 0.35 (0.25, 0.46)
Q4 (34.6–561.3) 0.48 (0.38, 0.58) 0.49 (0.39, 0.60) 0.38 (0.28, 0.48)* 0.38 (0.28, 0.49)* 0.38 (0.28, 0.48)* 0.30 (0.21, 0.41)
p-Trend 0.11 0.22 0.01 0.04 0.01 0.03
MEOHP (μg/L)
Q1 (≤ 5.44) 0.60 (0.49, 0.69) 0.58 (0.47, 0.68) 0.58 (0.47, 0.68) 0.56 (0.44, 0.66) 0.49 (0.39, 0.60) 0.47 (0.36, 0.58)
Q2 (5.45–10.4) 0.56 (0.45, 0.66) 0.57 (0.46, 0.67) 0.47 (0.37, 0.58) 0.48 (0.37, 0.59) 0.42 (0.32, 0.53) 0.42 (0.32, 0.53)
Q3 (10.5–24.7) 0.54 (0.43, 0.64) 0.54 (0.43, 0.64) 0.47 (0.37, 0.58) 0.47 (0.36, 0.58) 0.37 (0.27, 0.48) 0.36 (0.26, 0.47)
Q4 (24.8–306.0) 0.48 (0.38, 0.58) 0.50 (0.39, 0.60) 0.39 (0.29, 0.49)* 0.40 (0.30, 0.51)* 0.32 (0.23, 0.42)* 0.32 (0.22, 0.43)
p-Trend 0.14 0.26 0.03 0.07 0.03 0.07
MECPP (μg/L)
Q1 (≤ 14.5) 0.61 (0.50, 0.70) 0.59 (0.48, 0.69) 0.55 (0.45, 0.66) 0.54 (0.43, 0.64) 0.46 (0.36, 0.57) 0.43 (0.33, 0.54)
Q2 (14.6–26.2) 0.55 (0.44, 0.65) 0.55 (0.44, 0.66) 0.47 (0.37, 0.58) 0.48 (0.37, 0.58) 0.44 (0.34, 0.55) 0.43 (0.33, 0.54)
Q3 (26.3–56.6) 0.51 (0.41, 0.62) 0.52 (0.41, 0.62) 0.47 (0.37, 0.58) 0.47 (0.37, 0.58) 0.38 (0.28, 0.49) 0.37 (0.27, 0.48)
Q4 (56.7–760.5) 0.50 (0.40, 0.61) 0.51 (0.41, 0.62) 0.41 (0.31, 0.51) 0.42 (0.31, 0.52) 0.33 (0.24, 0.43) 0.32 (0.23, 0.43)
p-Trend 0.25 0.40 0.09 0.17 0.06 0.12
MEP (μg/L)
Q1 (≤ 21.4) 0.62 (0.52, 0.72) 0.60 (0.49, 0.70) 0.58 (0.48, 0.68) 0.55 (0.44, 0.66) 0.44 (0.34, 0.55) 0.40 (0.30, 0.51)
Q2 (21.5–49.2) 0.52 (0.42, 0.63) 0.53 (0.43, 0.64) 0.45 (0.35, 0.56) 0.46 (0.35, 0.56) 0.38 (0.29, 0.49) 0.38 (0.28, 0.49)
Q3 (49.3–128.1) 0.51 (0.41, 0.61) 0.52 (0.41, 0.62) 0.44 (0.34, 0.54) 0.44 (0.34, 0.55) 0.37 (0.27, 0.47) 0.36 (0.26, 0.47)
Q4 (128.2–3,481) 0.50 (0.40, 0.60) 0.52 (0.42, 0.63) 0.43 (0.33, 0.53)* 0.45 (0.34, 0.55) 0.40 (0.30, 0.51) 0.42 (0.31, 0.53)
p-Trend 0.25 0.55 0.17 0.40 0.87 0.65
MBP (μg/L)
Q1 (≤ 7.30) 0.63 (0.52, 0.72) 0.61 (0.50, 0.71) 0.55 (0.45, 0.65) 0.53 (0.42, 0.63) 0.48 (0.37, 0.58) 0.44 (0.34, 0.55)
Q2 (7.31–12.8) 0.57 (0.46, 0.66) 0.57 (0.46, 0.67) 0.50 (0.40, 0.60) 0.50 (0.40, 0.61) 0.41 (0.31, 0.52) 0.41 (0.31, 0.51)
Q3 (12.9–20.8) 0.47 (0.37, 0.57)* 0.48 (0.38, 0.59) 0.40 (0.30, 0.50)* 0.41 (0.31, 0.51) 0.36 (0.27, 0.47) 0.36 (0.27, 0.47)
Q4 (20.9–435.0) 0.50 (0.40, 0.60) 0.51 (0.41, 0.62) 0.45 (0.35, 0.55) 0.46 (0.36, 0.57) 0.35 (0.25, 0.45) 0.35 (0.25, 0.46)
p-Trend 0.10 0.22 0.17 0.36 0.09 0.19
MiBP (μg/L)
Q1 (≤ 3.50) 0.63 (0.52, 0.72) 0.62 (0.51, 0.72) 0.54 (0.44, 0.64) 0.53 (0.42, 0.63) 0.47 (0.36, 0.57) 0.44 (0.34, 0.55)
Q2 (3.51–6.63) 0.53 (0.43, 0.63) 0.53 (0.42, 0.63) 0.49 (0.39, 0.60) 0.48 (0.38, 0.59) 0.40 (0.30, 0.51) 0.39 (0.29, 0.49)
Q3 (6.64–12.0) 0.49 (0.39, 0.59) 0.51 (0.40, 0.62) 0.43 (0.33, 0.53) 0.44 (0.34, 0.55) 0.36 (0.27, 0.47) 0.37 (0.27, 0.48)
Q4 (12.1–49.7) 0.51 (0.41, 0.62) 0.52 (0.41, 0.63) 0.44 (0.34, 0.55) 0.44 (0.34, 0.55) 0.37 (0.27, 0.48) 0.36 (0.26, 0.47)
p-Trend 0.20 0.30 0.18 0.27 0.23 0.30
MBzP (μg/L)
Q1 (≤ 1.74) 0.55 (0.45, 0.65) 0.54 (0.43, 0.65) 0.50 (0.39, 0.60) 0.48 (0.38, 0.59) 0.41 (0.32, 0.52) 0.39 (0.29, 0.50)
Q2 (1.75–3.43) 0.58 (0.47, 0.68) 0.58 (0.47, 0.68) 0.48 (0.38, 0.59) 0.47 (0.37, 0.58) 0.37 (0.28, 0.48) 0.35 (0.25, 0.46)
Q3 (3.44–7.334) 0.54 (0.43, 0.64) 0.55 (0.45, 0.66) 0.48 (0.38, 0.59) 0.50 (0.39, 0.61) 0.46 (0.35, 0.56) 0.47 (0.37, 0.58)
Q4 (7.35–120.9) 0.50 (0.40, 0.61) 0.50 (0.40, 0.61) 0.44 (0.34, 0.55) 0.44 (0.33, 0.55) 0.36 (0.26, 0.47) 0.34 (0.25, 0.45)
p-Trend 0.37 0.44 0.44 0.51 0.53 0.59
MCPP (μg/L)
Q1 (≤ 1.80) 0.60 (0.50, 0.70) 0.60 (0.49, 0.70) 0.53 (0.43, 0.63) 0.52 (0.41, 0.63) 0.45 (0.34, 0.55) 0.43 (0.33, 0.54)
Q2 (1.81–3.19) 0.50 (0.40, 0.61) 0.50 (0.40, 0.61) 0.43 (0.33, 0.53) 0.42 (0.32, 0.53) 0.40 (0.30, 0.51) 0.39 (0.29, 0.50)
Q3 (3.20–6.58) 0.53 (0.42, 0.63) 0.53 (0.42, 0.63) 0.47 (0.37, 0.58) 0.47 (0.36, 0.57) 0.42 (0.32, 0.53) 0.41 (0.31, 0.52)
Q4 (6.59–202.2) 0.53 (0.43, 0.63) 0.55 (0.44, 0.65) 0.47 (0.37, 0.58) 0.48 (0.38, 0.59) 0.33 (0.24, 0.43) 0.32 (0.23, 0.43)
p-Trend 0.67 0.87 0.79 0.98 0.11 0.16
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levels of estradiol and progesterone are asso-
ciated with fetal loss (Schindler 2004), and 
thus DEHP may be operating through this 
hormonal pathway to increase the risk of early 
pregnancy loss. Our results raise concerns 
primarily about the potential of DEHP to 
result in lower probability of clinical preg-
nancy and live birth following ART.
One potential limitation of the present 
study is the generalizability of our findings to 
couples who conceive without medical assis-
tance. However, couples with infertility repre-
sent 10–15% of U.S. couples, and the number 
of couples undergoing infertility treatment is 
increasing. The number of ART births in the 
United States more than tripled from 1996 
to 2009 (ACOG Committee 1998; CDC/
ASRM/SART 2012). Based on this trend, the 
number of U.S. children born through ART 
over the next 10 years is expected to be well 
over 1 million (CDC/ASRM/SART 2012). 
We also have indirect evidence to support 
the generalizability of these results based on 
previous work among this cohort of couples 
undergoing IVF that have either been consis-
tent with, or since been corroborated by, 
other studies of non-IVF populations. Some 
examples include associations between phthal-
ates and lower male steroid hormones (Meeker 
et al. 2009; Mendiola et al. 2011; Pan et al. 
2006); pesticide exposure and semen quality 
(Meeker et al. 2008; Perry et al. 2007), thyroid 
hormone levels (Lacasaña et al. 2010; Meeker 
et al. 2006), and sperm DNA damage (Meeker 
et al. 2004; Xia et al. 2005); and self-reported 
maternal exposure to secondhand tobacco 
smoke and early pregnancy loss (Meeker 
et al. 2007a, 2007b; Peppone et al. 2009). Of 
interest, our decision to study the fertility clinic 
population was based on using an efficient 
design with sufficient power to investigate 
environmental influences on clinically relevant, 
yet previously unobservable, outcomes (e.g., 
fertilization rate and implantation) in a 
potentially vulnerable subpopulation. Thus, 
in summary, we believe that any potential 
limitations in generalizability in the proposed 
study are outweighed by its strengths because 
other study designs do not allow for the depth 
and breadth of exploration into these repro-
ductive health effects in such a cost-efficient 
manner. In addition, other strengths include 
state-of-the-art exposure biomarker measures 
at the CDC, clinical outcomes from electronic 
medical records, and collection of data on 
potential confounders.
Another potential limitation of the study is 
misclassification of exposure based on urinary 
concentrations of phthalate metabolites. Single 
measures of urinary biomarkers of exposure 
to these short-lived compounds may not 
represent exposure during critical windows 
that may span weeks (i.e., implantation) or 
months (i.e., miscarriage, live birth). We have 
conducted a study (Braun et al. 2012), as have 
others (Hoppin et al. 2002; Peck et al. 2010; 
Preau et al. 2010), that demonstrates low to 
moderate reproducibility (intraclass correla-
tions ranged from 0.15 to 0.65) of urinary 
levels of phthalate metabolites over time frames 
of weeks to a few months. Although it is well 
recognized that environmental exposures in 
close temporal proximity to the outcome are 
considered highly relevant, it is also important 
to consider that exposures distant from the 
outcome may also be relevant. For example, 
exposure very early in pregnancy may affect 
miscarriage later in pregnancy through effects 
on embryo quality and placentation. To reduce 
exposure misclassification in the present study, 
we collected two urine samples from each 
woman during each IVF cycle and used the 
geometric mean of the two cycle-specific urine 
concentrations as the exposure metric for the 
periconception exposure window.
In conclusion, using IVF as a model to 
investigate human reproduction and preg-
nancy outcomes, we found that concentrations 
of urinary metabolites of DEHP and DiDP 
were inversely associated with oocyte yield and 
number of MII oocytes at retrieval, whereas 
only metabolites of DiNP and DiDP were asso-
ciated with reduced fertilization rate. Urinary 
concentrations of DEHP metabolites were 
negatively associated with likelihood of clinical 
pregnancy and live birth following IVF. These 
results highlight the potential reproductive 
effects of low-level exposure (i.e., background 
exposure levels of the general population) to 
phthalates and adverse IVF outcomes.
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